BRPI0719174A2 - preparação de pirimidinas ribofuranosil nucleosídeos - Google Patents

preparação de pirimidinas ribofuranosil nucleosídeos

Info

Publication number: BRPI0719174A2
Authority: BR; Brazil
Prior art keywords: pyrimidines; preparation; ribofuranosyl nucleoside; ribofuranosyl; nucleoside
Prior art date: 2006-10-10

Application number

BRPI0719174A

Other languages

English (en)

Inventor

Ross Bruce

Chun Byoung-Kwon

Zhu Jiang

Vitale Justin

Sarma Keshab

Jin Qingwu

D Axt Steven

Rachakonda Suguna

Original Assignee

Hoffmann La Roche

Pharmasset Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-10

Filing date

2007-10-05

Publication date

2017-06-13

2007-10-05 Application filed by Hoffmann La Roche, Pharmasset Inc filed Critical Hoffmann La Roche

2017-06-13 Publication of BRPI0719174A2 publication Critical patent/BRPI0719174A2/pt

Links

239000002777 nucleoside Substances 0.000 title 1
-1 ribofuranosyl nucleoside pyrimidines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BRPI0719174A 2006-10-10 2007-10-05 preparação de pirimidinas ribofuranosil nucleosídeos BRPI0719174A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US85096206P	2006-10-10	2006-10-10
PCT/US2007/021548 WO2008045419A1 (en)	2006-10-10	2007-10-05	Preparation of nucleosides ribofuranosyl pyrimidines

Publications (1)

Publication Number	Publication Date
BRPI0719174A2 true BRPI0719174A2 (pt)	2017-06-13

Family

ID=39111500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0719174A BRPI0719174A2 (pt)	2006-10-10	2007-10-05	preparação de pirimidinas ribofuranosil nucleosídeos

Country Status (18)

Country	Link
US (2)	US8912321B2 (pt)
EP (1)	EP2084174B1 (pt)
JP (1)	JP5252459B2 (pt)
KR (1)	KR101057239B1 (pt)
CN (1)	CN101600725B (pt)
AU (1)	AU2007307057B2 (pt)
BR (1)	BRPI0719174A2 (pt)
CA (1)	CA2666098C (pt)
DK (1)	DK2084174T3 (pt)
ES (1)	ES2429290T3 (pt)
GT (1)	GT200900080A (pt)
IL (1)	IL198086A (pt)
MX (1)	MX2009003795A (pt)
PL (1)	PL2084174T3 (pt)
PT (1)	PT2084174E (pt)
RU (1)	RU2421461C2 (pt)
SI (1)	SI2084174T1 (pt)
WO (1)	WO2008045419A1 (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
HUE033832T2 (en)	2002-11-15	2018-01-29	Idenix Pharmaceuticals Llc	2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
EP2345657A1 (en)	2003-05-30	2011-07-20	Pharmasset, Inc.	Modified fluorinated nucleoside analogues
AU2005285045B2 (en) *	2004-09-14	2011-10-13	Gilead Sciences, Inc.	Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
ES2381982T3 (es)	2004-11-16	2012-06-04	Thomson Licensing	Método de simulación del grano de película basado en coeficientes de transformación previamente generados por ordenador
BRPI0517828A (pt)	2004-11-16	2008-10-21	Thomson Licensing	inserção de mensagens sei de grão de filme para uma simulação exata em bits em um sistema de vìdeo
ES2739452T3 (es)	2004-11-17	2020-01-31	Interdigital Vc Holdings Inc	Método de simulación de grano de película con precisión de bits basado en coeficientes transformados calculados previamente
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US10715834B2 (en)	2007-05-10	2020-07-14	Interdigital Vc Holdings, Inc.	Film grain simulation based on pre-computed transform coefficients
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
PT2376088T (pt)	2008-12-23	2017-05-02	Gilead Pharmasset Llc	Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
SG194404A1 (en) *	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Synthesis of purine nucleosides
KR20110098849A (ko)	2008-12-23	2011-09-01	파마셋 인코포레이티드	뉴클레오시드 유사체
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
UY33312A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Fosforamidato de nucleosido de purina
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt)	2010-03-31	2017-08-30	Gilead Pharmasset Llc	Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
JP5716500B2 (ja)	2010-06-03	2015-05-13	セントラル硝子株式会社	（２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類前駆体の製造方法
AU2011336632B2 (en)	2010-11-30	2015-09-03	Gilead Pharmasset Llc	Compounds
EP2691409B1 (en)	2011-03-31	2018-02-21	Idenix Pharmaceuticals LLC.	Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh)	2011-09-12	2013-07-16	Idenix Pharmaceuticals Inc	經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
PL2709613T5 (pl)	2011-09-16	2020-12-14	Gilead Pharmasset Llc	Metody leczenia hcv
US8507460B2 (en)	2011-10-14	2013-08-13	Idenix Pharmaceuticals, Inc.	Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
SE1450131A1 (sv)	2011-10-21	2014-05-07	Abbvie Inc	DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
DE112012002748T5 (de)	2011-10-21	2014-07-31	Abbvie Inc.	Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
CA2873315A1 (en)	2012-05-22	2013-11-28	Idenix Pharamaceuticals, Inc.	D-amino acid compounds for liver disease
WO2013177188A1 (en)	2012-05-22	2013-11-28	Idenix Pharmaceuticals, Inc.	3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en)	2012-05-22	2016-03-29	Idenix Pharmaceuticals, Inc.	3′,5′-cyclic phosphate prodrugs for HCV infection
SG11201407336PA (en)	2012-05-25	2015-03-30	Janssen Sciences Ireland Uc	Uracyl spirooxetane nucleosides
CN104379591A (zh)	2012-05-29	2015-02-25	弗·哈夫曼-拉罗切有限公司	用于制备2-脱氧-2-氟-2-甲基-d-呋喃核糖基核苷化合物的方法
CN103450148B (zh) *	2012-06-04	2018-06-12	浙江九洲药业股份有限公司	一种五元环硫酸酯化合物的合成方法
WO2014052638A1 (en)	2012-09-27	2014-04-03	Idenix Pharmaceuticals, Inc.	Esters and malonates of sate prodrugs
KR102001280B1 (ko)	2012-10-08	2019-07-17	아이데닉스 파마슈티칼스 엘엘씨	Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
CN103724301A (zh) *	2012-10-10	2014-04-16	上海特化医药科技有限公司	(2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
WO2014066239A1 (en)	2012-10-22	2014-05-01	Idenix Pharmaceuticals, Inc.	2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en)	2012-12-19	2015-10-28	IDENIX Pharmaceuticals, Inc.	4'-fluoro nucleosides for the treatment of hcv
CN103012386B (zh) *	2012-12-26	2015-04-01	浙江普洛得邦制药有限公司	一种五元环状硫酸酯的制备方法
PT2950786T (pt)	2013-01-31	2020-03-03	Gilead Pharmasset Llc	Formulação de combinação de dois compostos antivirais
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
US9309275B2 (en)	2013-03-04	2016-04-12	Idenix Pharmaceuticals Llc	3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en)	2013-03-04	2016-05-17	Merck Sharp & Dohme Corp.	Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en)	2013-03-13	2014-10-02	Idenix Pharmaceuticals, Inc.	Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en)	2013-04-01	2021-09-15	Idenix Pharmaceuticals LLC	2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en)	2013-06-05	2018-06-26	Idenix Pharmaceuticals Llc	1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en)	2013-08-01	2015-02-05	Idenix Pharmaceuticals, Inc.	D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru)	2013-08-27	2017-03-31	ГАЙЛИД ФАРМАССЕТ ЭлЭлСи	Комбинированный состав двух противовирусных соединений
CN104447923B (zh) *	2013-09-23	2018-03-30	中国药科大学	2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
WO2015161137A1 (en)	2014-04-16	2015-10-22	Idenix Pharmaceuticals, Inc.	3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US9675632B2 (en)	2014-08-26	2017-06-13	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
WO2016042576A1 (en)	2014-09-16	2016-03-24	Cadila Healthcare Limited	Co-crystal of sofosbuvir and amino acid and process for preparation thereof
CN104744539A (zh) *	2014-09-19	2015-07-01	上海皓元生物医药科技有限公司	一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的合成方法
CN104327138B (zh) *	2014-10-21	2017-05-10	齐鲁制药有限公司	Psi‑7977中间体化合物的制备方法
WO2016073756A1 (en)	2014-11-06	2016-05-12	Enanta Pharmaceuticals, Inc.	Deuterated nucleoside/tide derivatives
US9732110B2 (en)	2014-12-05	2017-08-15	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
CN104610404B (zh) *	2015-01-16	2016-04-06	南通常佑药业科技有限公司	一种呋喃核糖磷酸酯衍生物的制备方法
CA3182565A1 (en)	2015-03-06	2016-09-15	Atea Pharmaceuticals, Inc.	.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN104829672B (zh) *	2015-05-19	2018-03-13	江苏福瑞生物医药有限公司	一种药物中间体的合成方法
CN105061535A (zh) *	2015-09-02	2015-11-18	江苏科本医药化学有限公司	一种索非布韦中间体的合成方法
CN106554333B (zh) *	2015-09-29	2018-11-30	江苏福瑞生物医药有限公司	一种药物中间体的合成方法
CN106608896B (zh) *	2015-10-26	2019-08-27	江苏福瑞康泰药业有限公司	一种药物中间体的合成方法
CN105418547A (zh) *	2015-11-17	2016-03-23	海门慧聚药业有限公司	索非布韦关键中间体的制备
CN105503983B (zh) *	2015-12-17	2019-06-28	江苏阿尔法药业有限公司	索菲布韦中间体及其衍生物的制备方法
CN105566422B (zh) *	2015-12-29	2019-06-25	江苏阿尔法药业有限公司	索菲布韦中间体或其衍生物的制备方法
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10711029B2 (en)	2016-07-14	2020-07-14	Atea Pharmaceuticals, Inc.	Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en)	2016-07-20	2019-03-26	Optimus Drugs (P) Limited	Process for the preparation of sofosbuvir
DK3512863T3 (da)	2016-09-07	2022-03-07	Atea Pharmaceuticals Inc	2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN115477679A (zh)	2017-02-01	2022-12-16	阿堤亚制药公司	用于治疗丙型肝炎病毒的核苷酸半硫酸盐
CN106810515A (zh) *	2017-02-06	2017-06-09	抚州市星辰药业有限公司	一种合成索非布韦的中间体化合物及其合成方法
CN109422789A (zh) *	2017-08-28	2019-03-05	常州制药厂有限公司	一种索非布韦的制备工艺改进方法
EP3773753A4 (en)	2018-04-10	2021-12-22	ATEA Pharmaceuticals, Inc.	TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN108675984A (zh) *	2018-06-22	2018-10-19	江苏阿尔法药业有限公司	索非布韦中间体的制备方法
CN111606961A (zh) *	2019-02-26	2020-09-01	顾世海	一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的工艺生产方法
CN111040010A (zh) *	2019-12-23	2020-04-21	上海红蓝医药科技有限公司	一种索非布韦中间体的合成方法
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
KR20240022574A (ko)	2021-06-17	2024-02-20	아테아 파마슈티컬즈, 인크.	유리한 항-hcv 조합 요법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR850002973A (ko) *	1983-10-03	1985-05-28	구라바야시 이꾸시로	시티딘 유도체의 제조방법
JP2559917B2 (ja) *	1990-06-15	1996-12-04	三共株式会社	ピリミジンヌクレオシド誘導体
US5637688A (en) *	1994-12-13	1997-06-10	Eli Lilly And Company	Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
KR100719606B1 (ko) *	1998-02-25	2007-05-17	에모리 유니버시티	2'-플루오로뉴클레오사이드
SK1512002A3 (en)	1999-07-30	2002-11-06	Abbott Gmbh & Co Kg	2-pyrazolin-5-ones
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR20080021797A (ko)	2000-05-26	2008-03-07	이데닉스(케이만)리미티드	플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US7105499B2 (en) *	2001-01-22	2006-09-12	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2002057425A2 (en)	2001-01-22	2002-07-25	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002330154A1 (en)	2001-09-28	2003-04-07	Centre National De La Recherche Scientifique	Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
BR0312271A (pt)	2002-06-28	2007-11-06	Idenix Cayman Ltd	compostos, composições e seus usos para o tratamento de infecções por flaviviridae
PL374781A1 (en)	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) *	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
HUE033832T2 (en)	2002-11-15	2018-01-29	Idenix Pharmaceuticals Llc	2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) *	2002-11-19	2010-11-01	Hoffmann La Roche	Antiviral nucleoside derivatives
EP2345657A1 (en)	2003-05-30	2011-07-20	Pharmasset, Inc.	Modified fluorinated nucleoside analogues
EP1658302B1 (en)	2003-07-25	2010-08-25	IDENIX Pharmaceuticals, Inc.	Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
CN1863813B (zh) *	2003-08-27	2011-03-30	生物区科学管理控股有限公司	作为治疗剂的三环核苷或核苷酸
EP1741716B8 (en) *	2004-04-30	2012-02-22	Daiichi Sankyo Company, Limited	Process for producing pentacyclic taxane
AU2005267051B2 (en)	2004-07-21	2011-07-14	Gilead Sciences, Inc.	Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
AU2005285045B2 (en) *	2004-09-14	2011-10-13	Gilead Sciences, Inc.	Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

2007
- 2007-10-05 US US12/444,608 patent/US8912321B2/en active Active
- 2007-10-05 CN CN200780037855.XA patent/CN101600725B/zh active Active
- 2007-10-05 JP JP2009532372A patent/JP5252459B2/ja active Active
- 2007-10-05 MX MX2009003795A patent/MX2009003795A/es active IP Right Grant
- 2007-10-05 KR KR1020097008991A patent/KR101057239B1/ko active Active
- 2007-10-05 ES ES07839369T patent/ES2429290T3/es active Active
- 2007-10-05 EP EP07839369.1A patent/EP2084174B1/en active Active
- 2007-10-05 BR BRPI0719174A patent/BRPI0719174A2/pt not_active IP Right Cessation
- 2007-10-05 CA CA2666098A patent/CA2666098C/en active Active
- 2007-10-05 RU RU2009117396/04A patent/RU2421461C2/ru not_active IP Right Cessation
- 2007-10-05 SI SI200731311T patent/SI2084174T1/sl unknown
- 2007-10-05 PT PT78393691T patent/PT2084174E/pt unknown
- 2007-10-05 WO PCT/US2007/021548 patent/WO2008045419A1/en not_active Ceased
- 2007-10-05 DK DK07839369.1T patent/DK2084174T3/da active
- 2007-10-05 PL PL07839369T patent/PL2084174T3/pl unknown
- 2007-10-05 AU AU2007307057A patent/AU2007307057B2/en active Active
- 2007-10-10 US US11/973,748 patent/US20080139802A1/en not_active Abandoned
2009
- 2009-04-07 IL IL198086A patent/IL198086A/en active IP Right Grant
- 2009-04-13 GT GT200900080A patent/GT200900080A/es unknown

Also Published As

Publication number	Publication date
IL198086A (en)	2012-03-29
WO2008045419A1 (en)	2008-04-17
PL2084174T3 (pl)	2013-12-31
CN101600725A (zh)	2009-12-09
EP2084174B1 (en)	2013-07-31
JP5252459B2 (ja)	2013-07-31
CA2666098C (en)	2012-09-25
RU2421461C2 (ru)	2011-06-20
AU2007307057A1 (en)	2008-04-17
AU2007307057B2 (en)	2011-09-15
US20080139802A1 (en)	2008-06-12
JP2010505954A (ja)	2010-02-25
KR101057239B1 (ko)	2011-08-16
SI2084174T1 (sl)	2013-10-30
HK1133889A1 (en)	2010-04-09
RU2009117396A (ru)	2010-11-20
DK2084174T3 (da)	2013-11-04
US8912321B2 (en)	2014-12-16
CN101600725B (zh)	2014-11-26
GT200900080A (es)	2012-04-10
ES2429290T3 (es)	2013-11-14
IL198086A0 (en)	2009-12-24
MX2009003795A (es)	2009-06-18
EP2084174A1 (en)	2009-08-05
KR20090060460A (ko)	2009-06-12
US20100056770A1 (en)	2010-03-04
PT2084174E (pt)	2013-10-08
CA2666098A1 (en)	2008-04-17

Legal Events

Date	Code	Title	Description
2017-09-05	B25D	Requested change of name of applicant approved	Owner name: F. HOFFMANN-LA ROCHE AG (CH) , GILEAD PHARMASSET L
2017-09-26	B25G	Requested change of headquarter approved	Owner name: F. HOFFMANN-LA ROCHE AG (CH) , GILEAD PHARMASSET L
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-10-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 13A ANUIDADE.
2020-11-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-02-09	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0719174A2 (pt)	2017-06-13	preparação de pirimidinas ribofuranosil nucleosídeos
PT3133080T (pt)	2018-11-16	Nucleósidos de 7-deazapurina citostáticos inovadores
BRPI0819797A2 (pt)	2019-09-24	compostos de nucleosídeos antivirais
BRPI0716971A2 (pt)	2013-10-15	Uso de 2-6(3-amino-piperini-l-il)-3-metil-2,4-dioxo-3,4-dihidro-2 h-pirimidin-1ilmetil-4-fluoro-benxonitrila
SMT201400085B (it)	2014-09-08	Nucleosidi di uracile spiroosietano
BRPI0923815A2 (pt)	2015-07-14	Síntese de nucleosídeos de purina
BRPI0922508A2 (pt)	2015-08-11	Análogos de nucleosídeo
DK2114980T3 (da)	2012-09-24	Antivirale nukleosidanaloger
ES2465673T9 (es)	2014-11-14	Derivados de pirimidina
DK2114901T3 (da)	2014-06-30	Hiv-inhiberende 6-substituerede pyrimidiner
EP2029597A4 (en)	2011-11-23	purine analogs
BRPI0907435A2 (pt)	2015-07-14	Derivados de 5-flúor pirimidina
DOP2007000084A (es)	2007-12-31	Derivados de dihidropirazolopirimidinona
LTPA2014040I1 (lt)	2021-08-10	Nukleozidų fosforamidato provaistai
BRPI0817503A2 (pt)	2015-05-05	Derivados de purina substituídos por pirimidina
PT1943264E (pt)	2015-11-02	Análogos de oligonucleosídeos incorporando neles 5-azacitosina
DK2004632T3 (da)	2014-06-16	Hiv-inhiberende 5-amidosubstituerede pyrimidiner
BRPI0716936A2 (pt)	2013-09-17	derivados de adenosina como antigonistas de receptor de a2a
IL196583A0 (en)	2009-11-18	Antiviral use of cationic surfactant
BRPI0922681A2 (pt)	2016-01-05	nucleiotídeos de uracil ciclopropila
BRPI0916694A2 (pt)	2015-11-17	combinação antineoplásicas de 4-anilino-3-cianoquinolinas e capecitabina
BRPI0920496A2 (pt)	2019-09-24	derivados substituídos de pirimidina etriazina
BRPI0811115A2 (pt)	2014-12-23	Compostos de heteroarilamida pirimidona
CR10809A (es)	2009-06-25	Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
EP1994042A4 (en)	2009-03-18	PREPARATION OF GEMCITABINE